PA-9
PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC50 of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain[1].
Product Specifications
CAS Number
[1436004-46-4]
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
PACAP Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/pa-9.html
Purity
99.73
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(C(C1)CN(C2=NNC3=C2C=CC=C3)C1=O)NCCC4=CN=CN4
Molecular Formula
C17H18N6O2
Molecular Weight
338.36
Precautions
H315, H319, H335
References & Citations
[1]Takasaki I, et al. In Silico Screening Identified Novel Small-molecule Antagonists of PAC1 Receptor. J Pharmacol Exp Ther. 2018 Apr;365 (1) :1-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Lodderomyces elongisporus Actin cytoskeleton-regulatory complex protein END3 (END3)
Recombinant Lodderomyces elongisporus Actin cytoskeleton-regulatory complex protein END3 (END3)
Recombinant Lodderomyces elongisporus Actin cytoskeleton-regulatory complex protein END3 (END3)
Recombinant Lodderomyces elongisporus Actin cytoskeleton-regulatory complex protein END3 (END3)
Recombinant Lodderomyces elongisporus Actin cytoskeleton-regulatory complex protein END3 (END3)